ESMO Open Oncology

Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →